Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases. Located in the historic Dogpatch area of San Francisco, we are a part of the innovative incubator program offered by QB3@953.
Location: United States, California, San Francisco
Employees: 11-50
Phone: +1 415-991-0947
Total raised: $42M
Founded date: 2016
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.03.2024 | Series C | $12M | - |
| 22.09.2020 | Series B | $30M | - |
Mentions in press and media 8
| Date | Title | Description |
| 15.03.2024 | Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development | The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's... |
| 13.03.2024 | Siolta Therapeutics Raises $12M in Series C Funding | Siolta Therapeutics, a San Carlos, CA-based clinical-stage biotech company, raised $12M in Series C funding. The round was led by SymBiosis and Khosla Ventures, with participation of existing investors. The company intends to use the funds ... |
| 13.03.2024 | Siolta Therapeutics Scoops Up $12M Series C | SAN CARLOS, CA, Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. >> Click here for more funding data on Siolta Therapeutics >> To export Siolta Th... |
| 22.09.2020 | Clinical-Stage Biotech Company Siolta Therapeutics Raises $30 Million | Clinical-stage biotech company Siolta Therapeutics announced it raised $30 million in Series B funding to support the clinical development of its lead product STMC-103H Clinical-stage biotech company Siolta Therapeutics announced it raised ... |
| 22.09.2020 | Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases | - |
| 22.09.2020 | Siolta Therapeutics : Raises $30M Series B for the Prevention and Treatment of Allergic Diseases | Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from to... |
| 22.09.2020 | Siolta Therapeutics Raises $30M in Series B Funding | Siolta Therapeutics, a San Carlos, Calif.-based clinical-stage biotech company, raised $30M in series B funding. backers included series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capita... |
| - | Siolta Therapeutics | “Siolta Therapeutics is a clinical-stage company developing live biotherapeutics that target the core drivers of disease. Learn more.” |